Compare Public Storage (PSA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Sana Biotechnology Inc — how do they compare? Public Storage trades at $294.6 (market cap $55.59B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Public Storage is far larger — about 54× Sana Biotechnology Inc's market cap, and Public Storage pays a 3.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PSA | SANA | |
|---|---|---|
Market Cap | $55.59B | $1.03B |
Sector | Real Estate | Health |
52-Week High | $330.47 | $5.92 |
52-Week Low | $258.44 | $2.68 |
Enterprise Value | $69.86B | $946.04M |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $301.6, down slightly by 0.14% today, with a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Recent developments include the completion of the Public Storage Canada acquisition and a C$400 million senior notes offering in Canada. Valuation ratios are elevated, with a P/E of 28.82 and P/S of 10.88, while profitability remains strong with a net income margin of 41.8%.
The outlook is mixed: strong fundamentals and dividend payments support the stock, but high valuation and bearish technicals pose risks. Analyst consensus is a 'Hold' with a price target of $334.13, suggesting modest upside. Key risks include execution of recent acquisitions and sensitivity to interest rate changes. Investors should weigh solid earnings performance against premium valuation.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
